Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Quality of Life

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Abstract

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell count30 × 109/L and plts count 450 × 109/L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio=1.7, P=0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011; 9: S1–S25.

    Article  CAS  Google Scholar 

  2. Goldman JM . Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009; 2009: 453–460.

    Article  Google Scholar 

  3. Goldman JM . Treatment strategies for CML. Best Pract Res Clin Haematol 2009; 22: 303–313.

    Article  CAS  Google Scholar 

  4. Pavlu J, Szydlo RM, Goldman JM, Apperley JF . Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755–763.

    Article  CAS  Google Scholar 

  5. Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander AR, Baccarani M et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011; 126: 30–39.

    Article  CAS  Google Scholar 

  6. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006 91: 513–521.

  7. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.

    Article  CAS  Google Scholar 

  8. Pasquini MC . Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 2012; 17: S79–S82.

    Article  Google Scholar 

  9. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117: 5591–5599.

    Article  CAS  Google Scholar 

  10. Goldman JM . How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828–2837.

    Article  CAS  Google Scholar 

  11. Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M . Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors—the first molecular targeted treatment. J Med Life 2010; 3: 162–166.

    PubMed  PubMed Central  Google Scholar 

  12. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21: 2138–2146.

    Article  CAS  Google Scholar 

  13. Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A . Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011; 52: 1017–1023.

    Article  CAS  Google Scholar 

  14. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118: 4554–4560.

    Article  CAS  Google Scholar 

  15. Chang G, Orav EJ, McNamara TK, Tong MY, Antin JH . Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics 2005; 46: 34–40.

    Article  Google Scholar 

  16. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA . Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20: 2334–2343.

    Article  CAS  Google Scholar 

  17. Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 2013; 27: 2410–2413.

    Article  CAS  Google Scholar 

  18. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A . Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33: AS264–AS279.

    Article  Google Scholar 

  19. Li L, Wang HM, Shen Y . Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003; 57: 259–263.

    Article  CAS  Google Scholar 

  20. Chen Z, Wang C, Xu X, Feng W . Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health 2009; 12: S85–S88.

    Article  Google Scholar 

  21. Liang Y, Lai Y, Schwarzenberger P, Li Q, Ma J, Luo J et al. Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrowtransplantation for that disease? Biol Blood Marrow Transplant 2010; 16: 848–853.

    Article  CAS  Google Scholar 

  22. Sutherland HJ, Fyles GM, Adams G, Hao Y, Lipton JH . Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19: 1129–1136.

    Article  CAS  Google Scholar 

  23. Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997; 126: 184–192.

    Article  CAS  Google Scholar 

  24. Bush NE, Donaldson GW, Haberman MH, Dacanay R, Sullivan KM . Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant 2000; 6: 576–591.

    Article  CAS  Google Scholar 

  25. Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint MT, Lamparelli T et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110: 614–619.

    Article  CAS  Google Scholar 

  26. Bevans MF, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P et al. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 101–109.

    Article  CAS  Google Scholar 

  27. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827–2832.

    Article  CAS  Google Scholar 

  28. Lakshmaiah K, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM et al. Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinib mesylate. Leuk Lymphoma 2012; 53: 2430–2433.

    Article  CAS  Google Scholar 

  29. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–916.

    Article  Google Scholar 

  30. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK . Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012; 59: 481–484.

    Article  Google Scholar 

  31. Andolina JR, Neudorf SM, Corey SJ . How I treat childhood CML. Blood 2012; 119: 1821–1830.

    Article  CAS  Google Scholar 

  32. Suttorp M, Yaniv I, Schultz KR . Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011; 17: S115–S122.

    Article  Google Scholar 

  33. Weisser M, Ledderose G, Jochem Kolb H . Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Ann Hematol 2007; 86: 127–132.

    Article  Google Scholar 

  34. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799.

    CAS  Google Scholar 

  35. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858.

    Article  CAS  Google Scholar 

  36. Mo XD, Xu LP, Liu DH, Chen YH, Han W, Zhang XH et al. Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT. Bone Marrow Transplant 2012; 47: 1201–1205.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the medical editors at Editage, who provided editing assistance to the authors during the preparation of this manuscript.This work was supported by the Key Program of National Natural Science Foundation of China (Grant No. 81230013) and the Beijing Municipal Science & Technology Commission (Z111107067311070).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to X-J Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mo, XD., Jiang, Q., Xu, LP. et al. Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49, 576–580 (2014). https://doi.org/10.1038/bmt.2013.232

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.232

Keywords

This article is cited by

Search

Quick links